4620 Creekstone Drive
About Alcami Corporation
About Alcami Corporation
Alcami is a world-class contract development and manufacturing organization (CDMO) headquartered in North Carolina, with executive offices in Durham and Wilmington. With over 1,000 employees operating at TEN global locations, Alcami provides customizable and innovative services to small and mid-size pharmaceutical and biotechnology companies by offering individualized and integrated services across multiple areas. We connect our clients with innovative solutions for API development and manufacturing, solid-state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services.
For more information, please visit www.alcaminow.com.
We are a team of dynamic individuals committed to developing life-saving drugs around the world. A mindset of innovation, accountability, and customer focus inspires us to be the most efficient, safe, and reliable choice for our customers and the patients they serve. In return, we offer challenging careers, accelerated professional growth, and the opportunity to be part of something different.
33 articles with Alcami Corporation
Alcami, a US-based contract development and manufacturing organization (CDMO), announced today that it is providing commercial manufacturing services for Trevena's newly approved OLINVYK. OLINVYK (oliceridine) injection is an opioid approved in adults for the management of acute pain severe enough to require an intravenous opioid
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Alcami, a United States -based contract development and manufacturing organization (CDMO), announced today the appointment of Walter J. Kaczmarek III as Chief Executive Officer. Mr. Kaczmarek, who has over 30 years of experience in the pharmaceutical industry, will focus on advancing Alcami's next phase of strategic growth.
Alcami Continues to Strengthen Senior Leadership Team with Appointment of Quality and Regulatory Leaders
Alcami, a North Carolina-based contract development and manufacturing organization, announced further additions to strengthen its senior leadership team.
Alcami, a North Carolina-based contract development and manufacturing organization, announced the appointment of Ken Domagalski and Elliott Franco to their Senior Leadership Team.
Transaction Advances Alcami's Strategic Plan by Adding Scale in Attractive and Growing Parenteral Markets
Next Step in Alcami's Strategic Plan to Focus its Platform on High-Growth Market Segments
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, launched Alcami Biologics, the organization's new biopharmaceutical development, analytical testing, manufacturing, and packaging enterprise.
Alcami Helps Medicines Development for Global Health Secure FDA Approval of Moxidectin for River Blindness
Alcami Corporation announced today its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit Australian biopharmaceutical company dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low and middle-income countries.
Alcami Corporation announced a renewed partnership with the Wisconsin Department of Natural Resources (DNR) to revitalize and repair the Hank Aaron State Trail in Milwaukee, Wisconsin, and the Pike Lake Hiking Trail in Hartford, Wisconsin.
Alcami Corporation announced today its $15,000 donation to the Wilmington, North Carolina Fire Department (WFD) to help fund IvyGene® cancer screenings for firefighters.
Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Alcami Corporation announced the expanded deployment of its Extended Workbench laboratory services program to support the ongoing manufacturing and development of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension).
Alcami to Become Industry Leading Platform CDMO Following Acquisition by Madison Dearborn Partners - duplicate
Alcami Corporation announced it has reached an agreement to be acquired by Madison Dearborn Partners, LLC (MDP).
MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation
Alcami continues to set the industry standard with its analytical testing offering, and through operational excellence, streamlined processes, and technical knowledge and expertise, has reduced timelines by up to 30 percent.
Alcami Corporation announces the Missouri House of Representatives and St. Louis Mayor Lyda Krewson will honor Alcami with a resolution and letter of commendation.
The Kendall Square facility will support robust customer growth and connect Alcami to the forefront of hundreds of thriving pharma and biotech start-ups and innovators.
The facility will support the company's thriving West Coast customer base and will help accelerate growth through new regional partnerships.
Alcami Announces Manufacturing Agreement for Solasia's Active Pharmaceutical Ingredient Darinaparsin
The company has finalized manufacturing and quality agreements with Solasia Pharma, K.K.